AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27627987 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants in VEGF
Number of subjects: 0
Study 27627987 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27628064 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Number of subjects: 12
Study 27628323 — intervention group
Group type: EXPERIMENTAL
Intervention: JE-CV booster dose
Number of subjects: 50
Study 27628523 — intervention group
Group type: EXPERIMENTAL
Intervention: Simtomax
Number of subjects: 934
Study 27628523 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA-TTG
Number of subjects: 934
Study 27628523 — intervention group
Group type: EXPERIMENTAL
Intervention: EMA
Number of subjects: 934
Study 27629052 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriers of the minor C allele at the PLIN1 6209T>C variant
Number of subjects: 1287
Study 27629052 — intervention group
Group type: EXPERIMENTAL
Intervention: AA carriers eating late
Number of subjects: 1287
Study 27629052 — intervention group
Group type: COMPARATOR
Intervention: TT carriers
Number of subjects: 1287
Study 27629486 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 stimulation in T cells from individuals with T1D
Number of subjects: 0
Study 27629486 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 stimulation in CD4(+) T cells from patients with T1D
Number of subjects: 0
Study 27629486 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6-targeted therapeutic intervention (currently being tested, NCT02293837)
Number of subjects: 0
Study 27629548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multidisciplinary team intervention
Number of subjects: 0
Study 27629548 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 27629548 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary interventions
Number of subjects: 0
Study 27629938 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Sleep Questionnaire (PSQ)
Number of subjects: 45
Study 27629938 — intervention group
Group type: EXPERIMENTAL
Intervention: Sagittal abdominal diameter
Number of subjects: 45
Study 27630075 — intervention group
Group type: EXPERIMENTAL
Intervention: Autism Spectrum Disorder (ASD)
Number of subjects: 23
Study 27630075 — intervention group
Group type: COMPARATOR
Intervention: Attention Deficit Hyperactivity Disorder (ADHD)
Number of subjects: 23
Study 27630075 — intervention group
Group type: COMPARATOR
Intervention: Healthy male controls
Number of subjects: 23
Study 27630075 — intervention group
Group type: EXPERIMENTAL
Intervention: ASD
Number of subjects: 23
Study 27630340 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green fluorescence imaging (ICG-FI)
Number of subjects: 20
Study 27630340 — intervention group
Group type: COMPARATOR
Intervention: Patent blue (PB)
Number of subjects: 20
Study 27630572 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily consumption of five or more medicinal molecules
Number of subjects: 113
Study 27631025 — intervention group
Group type: EXPERIMENTAL
Intervention: lasR mutant strains of Pseudomonas aeruginosa
Number of subjects: 101
Study 27631025 — intervention group
Group type: COMPARATOR
Intervention: LasR-intact strains of Pseudomonas aeruginosa
Number of subjects: 101
Study 27631092 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25OHD) levels below identified cut-points
Number of subjects: 344
Study 27631092 — intervention group
Group type: COMPARATOR
Intervention: Serum 25-hydroxyvitamin D (25OHD) levels above identified cut-points
Number of subjects: 344
Study 27631751 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Ji Quan: Moving for Better Balance (TJQMBB) program
Number of subjects: 36
Study 27632289 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2-targeted therapy (trastuzumab/pertuzumab)
Number of subjects: 226
Study 27632289 — intervention group
Group type: COMPARATOR
Intervention: PRO Onc assay
Number of subjects: 226
Study 27632680 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor-modified T cell therapy
Number of subjects: 39
Study 27632680 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (interleukin-6 receptor antibody)
Number of subjects: 39
Study 27632776 — intervention group
Group type: EXPERIMENTAL
Intervention: Excess gestational weight gain (GWG)
Number of subjects: 40
Study 27633122 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandoz biosimilar filgrastim, administered twice daily
Number of subjects: 245
Study 27633122 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandoz biosimilar filgrastim
Number of subjects: 245
Study 27633375 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher tertile of TyG index
Number of subjects: 888
Study 27633375 — intervention group
Group type: COMPARATOR
Intervention: Lower tertile of TyG index
Number of subjects: 888
Study 27633375 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of TyG index
Number of subjects: 888
Study 27633393 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) of atrial fibrillation (AF)
Number of subjects: 192
Study 27633513 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.01%
Number of subjects: 312
Study 27633639 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper body progressive resistance training and diet counselling to correct deficiencies in nutrient intake plus counselling on caloric restriction and aerobic exercise to achieve a weight loss of 0.68-0.919 kg/week
Number of subjects: 40
Study 27633639 — intervention group
Group type: COMPARATOR
Intervention: Upper body progressive resistance training and diet counselling to correct deficiencies in nutrient intake
Number of subjects: 40
Study 27634203 — intervention group
Group type: EXPERIMENTAL
Intervention: Momelotinib 200 mg twice daily
Number of subjects: 61
Study 27634566 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib at 800 mg oral daily until disease progression
Number of subjects: 17
Study 27635072 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive cardiac workup including ECG, signal averaged ECG, exercise testing, cardiac imaging, Holter-monitoring, and selective provocative drug testing with epinephrine or procainamide
Number of subjects: 398
Study 27635072 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing performed when a mutation was identified or phenotype suggestive of inherited arrhythmia syndrome
Number of subjects: 398
Study 27635072 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic cascade screening and genetic testing
Number of subjects: 398
Study 27635086 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C Metabolic MRI
Number of subjects: 4
Study 27635086 — intervention group
Group type: COMPARATOR
Intervention: Conventional proton cardiac magnetic resonance imaging
Number of subjects: 4
Study 27635623 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) delivered in 5 fractions to a dose of 25 to 40 Gy
Number of subjects: 11
Study 27635623 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR)
Number of subjects: 11
Study 27636157 — intervention group
Group type: EXPERIMENTAL
Intervention: Probable PTSD
Number of subjects: 810
Study 27636157 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy drinking
Number of subjects: 810
Study 27636157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine use
Number of subjects: 810
Study 27636157 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner physical violence
Number of subjects: 810
Study 27636400 — intervention group
Group type: EXPERIMENTAL
Intervention: FLARE-RA self-administered questionnaire
Number of subjects: 138
Study 27636672 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education (proxy for cognitive reserve)
Number of subjects: 90
Study 27636672 — intervention group
Group type: EXPERIMENTAL
Intervention: High WMH volume among highly educated participants
Number of subjects: 90
Study 27636672 — intervention group
Group type: EXPERIMENTAL
Intervention: Low WMH volume among highly educated participants
Number of subjects: 90
Study 27636722 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 53
Study 27637014 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibin B (INHB) <50 ng/dL
Number of subjects: 93
Study 27637014 — intervention group
Group type: EXPERIMENTAL
Intervention: Low INHB
Number of subjects: 93
Study 27637014 — intervention group
Group type: EXPERIMENTAL
Intervention: Total testosterone (TT)
Number of subjects: 93
Study 27637014 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-mullerian hormone (AMH)
Number of subjects: 93
Study 27637014 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertoli cell dysfunction
Number of subjects: 93
Study 27637340 — intervention group
Group type: EXPERIMENTAL
Intervention: 800mg DHA/day during pregnancy (DOMInO trial)
Number of subjects: 300000
Study 27637340 — intervention group
Group type: EXPERIMENTAL
Intervention: 600mg DHA/day during pregnancy (KUDOS trial)
Number of subjects: 300000
Study 27637340 — intervention group
Group type: COMPARATOR
Intervention: Placebo during pregnancy (both trials)
Number of subjects: 300000
Study 27637428 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin at 14 mg/m²
Number of subjects: 30
Study 27637497 — intervention group
Group type: EXPERIMENTAL
Intervention: Livelihood intervention (microfinance loan, agricultural and financial training, human-powered water pump)
Number of subjects: 117
Study 27637497 — intervention group
Group type: EXPERIMENTAL
Intervention: Livelihood intervention
Number of subjects: 117
Study 27637985 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg orally once daily until progressive disease or unacceptable toxicity
Number of subjects: 144
Study 27639327 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 831
Study 27639327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 831
Study 27640066 — intervention group
Group type: EXPERIMENTAL
Intervention: Supracervical hysterectomy
Number of subjects: 212
Study 27640066 — intervention group
Group type: COMPARATOR
Intervention: Total abdominal hysterectomy
Number of subjects: 212
Study 27641497 — intervention group
Group type: EXPERIMENTAL
Intervention: Back on Track intervention (biopsychosocial primary care intervention)
Number of subjects: 0
Study 27641687 — intervention group
Group type: EXPERIMENTAL
Intervention: CRISPR-Cas9 genome editing technique
Number of subjects: 0
Study 27641687 — intervention group
Group type: EXPERIMENTAL
Intervention: CRISPR-Cas9
Number of subjects: 0
Study 27641715 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical release of tongue-tie/lip-tie
Number of subjects: 237
Study 27641715 — intervention group
Group type: COMPARATOR
Intervention: Preoperative breastfeeding measures
Number of subjects: 237
Study 27642132 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-D (0.5-mL booster dose)
Number of subjects: 834
Study 27642534 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training (a combination of aerobic, resistance, and flexibility exercises, average of 2.5 hours a week)
Number of subjects: 43
Study 27642534 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 43
Study 27642538 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin (0.02 mg/kg BID at Week 1, 0.04 mg/kg BID at Week 2, maximum 0.08 mg/kg BID thereafter)
Number of subjects: 23
Study 27642538 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin
Number of subjects: 23
Study 27642657 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock anticipation
Number of subjects: 0
Study 27642657 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear-potentiated startle
Number of subjects: 0
Study 27642657 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat-related/task-unrelated thoughts
Number of subjects: 0
Study 27643438 — intervention group
Group type: EXPERIMENTAL
Intervention: WASP-deficient Tregs
Number of subjects: 0
Study 27643438 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional deletion of Was in FOXP3+ Tregs
Number of subjects: 0
Study 27643485 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg, two infusions
Number of subjects: 24
Study 27644174 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced dental maturity group
Number of subjects: 111
Study 27644174 — intervention group
Group type: COMPARATOR
Intervention: Delayed and average dental maturity groups
Number of subjects: 111
Study 27644469 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab injections
Number of subjects: 3414
Study 27644734 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal gluten immunogenic peptides (GIP) measured by ELISA
Number of subjects: 188
Study 27644734 — intervention group
Group type: COMPARATOR
Intervention: Dietary questionnaire
Number of subjects: 188
Study 27644734 — intervention group
Group type: COMPARATOR
Intervention: Anti-tissue transglutaminase (anti-tTG) IgA antibodies
Number of subjects: 188
Study 27644734 — intervention group
Group type: COMPARATOR
Intervention: Anti-deamidated gliadin peptide (anti-DGP) IgA antibodies
Number of subjects: 188
Study 27645461 — intervention group
Group type: EXPERIMENTAL
Intervention: Eotaxin levels
Number of subjects: 27
Study 27646946 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously once every 3 weeks
Number of subjects: 132
Study 27647056 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco Tactics intervention
Number of subjects: 1528
Study 27647168 — intervention group
Group type: EXPERIMENTAL
Intervention: NOACs (Novel Oral Anticoagulants)
Number of subjects: 39670
Study 27647168 — intervention group
Group type: COMPARATOR
Intervention: VKA±AP (Vitamin K Antagonists plus Antiplatelet) or AP (Antiplatelet) alone
Number of subjects: 39670
Study 27647694 — intervention group
Group type: EXPERIMENTAL
Intervention: Insular infarction
Number of subjects: 736
Study 27647694 — intervention group
Group type: COMPARATOR
Intervention: No insular infarction
Number of subjects: 736
Study 27647694 — intervention group
Group type: EXPERIMENTAL
Intervention: Right insular infarction
Number of subjects: 736
Study 27647864 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (25 mg, days 1-21/28 days) + continuous cyclophosphamide (50 mg/d) + prednisone (20 mg/d)
Number of subjects: 67
Study 27648287 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline fitness (measured by treadmill duration)
Number of subjects: 3358
Study 27648287 — intervention group
Group type: COMPARATOR
Intervention: Modified Mediterranean diet pattern
Number of subjects: 3358
Study 27648286 — intervention group
Group type: EXPERIMENTAL
Intervention: Technosphere inhaled insulin (TI) during URTI
Number of subjects: 20
Study 27648290 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-specific oral nutritional supplement (ONS)
Number of subjects: 12
Study 27648290 — intervention group
Group type: COMPARATOR
Intervention: Standard oral nutritional supplement (ONS)
Number of subjects: 12
Study 27648294 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 60 mg/m² on day 1 and capecitabine 900 mg/m² two times per day from day 1 to day 14 every 3 weeks (2 cycles)
Number of subjects: 18
Study 27648294 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and capecitabine
Number of subjects: 18
Study 27648659 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol levels in women with AHI ≥15 (moderate-to-severe OSA)
Number of subjects: 30
Study 27648659 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher estradiol levels
Number of subjects: 30
Study 27648659 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol levels after adjusting for age and BMI
Number of subjects: 30
Study 27649801 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant BMI peak characteristics
Number of subjects: 1020
Study 27649801 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant BMI peak
Number of subjects: 1020
Study 27649801 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at peak BMI
Number of subjects: 1020
Study 27649801 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak magnitude
Number of subjects: 1020
Study 27649801 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age and higher magnitude at peak
Number of subjects: 1020
Study 27649801 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnic-specific differences in BMI peak characteristics
Number of subjects: 1020
Study 27649927 — intervention group
Group type: EXPERIMENTAL
Intervention: Perifosine 50-75 mg
Number of subjects: 0
Study 27650225 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone (24mcg b.i.d., P.O. for 2 weeks)
Number of subjects: 29
Study 27650271 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided pancreatic cyst ablation (PCA) with ethanol alone (n=8) or ethanol and paclitaxel (n=28)
Number of subjects: 36
Study 27650271 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided pancreatic cyst ablation (PCA)
Number of subjects: 36
Study 27650284 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time US-CT/MR fusion imaging guidance
Number of subjects: 216
Study 27650284 — intervention group
Group type: COMPARATOR
Intervention: B-mode US
Number of subjects: 216
Study 27650283 — intervention group
Group type: EXPERIMENTAL
Intervention: SHBs mutants with amino acid substitutions
Number of subjects: 230
Study 27650283 — intervention group
Group type: COMPARATOR
Intervention: Wild-type HBsAg
Number of subjects: 230
Study 27650283 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated CHB patients with novel SHBs mutations
Number of subjects: 230
Study 27650822 — intervention group
Group type: EXPERIMENTAL
Intervention: Early β blockers (≤48 hours of admission)
Number of subjects: 2679
Study 27650822 — intervention group
Group type: EXPERIMENTAL
Intervention: β blockers at discharge
Number of subjects: 2679
Study 27650822 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistence of β blockers at one year
Number of subjects: 2679
Study 27650822 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing statins at one year
Number of subjects: 2679
Study 27651231 — intervention group
Group type: EXPERIMENTAL
Intervention: ROP telemedicine evaluation system
Number of subjects: 292
Study 27651231 — intervention group
Group type: EXPERIMENTAL
Intervention: Image sets submitted before 2 p.m. EST
Number of subjects: 292
Study 27651231 — intervention group
Group type: EXPERIMENTAL
Intervention: Image sets submitted after 2 p.m. EST
Number of subjects: 292
Study 27651304 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal fitness tracker (PFT)
Number of subjects: 50
Study 27651304 — intervention group
Group type: COMPARATOR
Intervention: Pulse oximetry (Spo2.R)
Number of subjects: 50
Study 27651390 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI) with drug-eluting stents
Number of subjects: 1166
Study 27651390 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 1166
Study 27651390 — intervention group
Group type: COMPARATOR
Intervention: All-cause mortality
Number of subjects: 1166
Study 27651390 — intervention group
Group type: COMPARATOR
Intervention: Stroke
Number of subjects: 1166
Study 27651793 — intervention group
Group type: EXPERIMENTAL
Intervention: DM-1 group
Number of subjects: 42
Study 27651793 — intervention group
Group type: COMPARATOR
Intervention: Reference group
Number of subjects: 42
Study 27651909 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) containing fluticasone propionate
Number of subjects: 0
Study 27651909 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27652031 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric exercise (CE)
Number of subjects: 7
Study 27652031 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise (EE)
Number of subjects: 7
Study 27652248 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental presence (fathers)
Number of subjects: 122
Study 27652248 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental presence (mothers)
Number of subjects: 122
Study 27652248 — intervention group
Group type: COMPARATOR
Intervention: No parental presence
Number of subjects: 122
Study 27652687 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific instrumentation (PSI)
Number of subjects: 128
Study 27652687 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigated computer-assisted surgery (CAS)
Number of subjects: 128
Study 27652687 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKA surgical techniques
Number of subjects: 128
Study 27653085 — intervention group
Group type: EXPERIMENTAL
Intervention: MedGem (MG)
Number of subjects: 54
Study 27653085 — intervention group
Group type: COMPARATOR
Intervention: Standard indirect calorimeter (VMax)
Number of subjects: 54
Study 27653085 — intervention group
Group type: COMPARATOR
Intervention: MedGem (MG) vs VMax
Number of subjects: 54
Study 27653529 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b therapy
Number of subjects: 445
Study 27653565 — intervention group
Group type: EXPERIMENTAL
Intervention: KAF156 multiple doses (400 mg once daily for 3 days)
Number of subjects: 41
Study 27653565 — intervention group
Group type: EXPERIMENTAL
Intervention: KAF156 single dose (800 mg)
Number of subjects: 41
Study 27653771 — intervention group
Group type: EXPERIMENTAL
Intervention: Single challenge dose of monovalent pediatric hepatitis B vaccine (Engerix™-B Kinder; GSK Vaccines)
Number of subjects: 300
Study 27653771 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-challenge adverse events (AEs) monitoring
Number of subjects: 300
Study 27654119 — intervention group
Group type: EXPERIMENTAL
Intervention: GooDMomS program (web-based intervention)
Number of subjects: 23
Study 27654603 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-TNF-targeted biologic
Number of subjects: 300
Study 27654603 — intervention group
Group type: COMPARATOR
Intervention: Second anti-TNF drug
Number of subjects: 300
Study 27654882 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin 500 mg q1h for 4 doses
Number of subjects: 12
Study 27654882 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin 500 mg q2h for 3 doses
Number of subjects: 12
Study 27654882 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin 250 mg q2h for 3 doses
Number of subjects: 12
Study 27654985 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenapanor hydrochloride (15 mg twice daily) with sevelamer carbonate (800 mg 3 times daily)
Number of subjects: 0
Study 27654985 — intervention group
Group type: COMPARATOR
Intervention: Tenapanor hydrochloride (15 mg twice daily) without sevelamer carbonate
Number of subjects: 0